Photon-counting CT breaks new ground in pancreatic cancer precision imaging
Novel PCCT boosts tumor visualization, vascular mapping, and surgical navigation for lethal pancreatic cancer
image: (A) A panoramic view displays branches of the celiac artery. (B) Focused view highlights fine peripancreatic arterial branches. (C) Color-coded reconstruction emphasizes the pancreatic duct (blue), showing mild upstream ductal dilation. CR = cinematic rendering; PCCT = photon-counting computed tomography.
Credit: Liang Zhu and Weibin Wang from Peking Union Medical College, China Image source link: https://journals.lww.com/jpancreatology/fulltext/2026/03000/photon_counting_ct_for_pancreatic_cancer_.3.aspx
A new review published in the Journal of Pancreatology highlights that photon-counting computed tomography (PCCT, or PCD-CT) is transforming precision imaging and surgical navigation for pancreatic cancer, a disease with a 5-year survival rate below 15%.
Conventional energy-integrating detector CT (EIDCT) often fails to clearly delineate pancreatic tumor boundaries and adjacent anatomy, especially for low-contrast lesions. Up to 45% of pancreatic ductal adenocarcinomas (PDACs) show iso-enhancement on EIDCT, complicating detection. It also has limited accuracy for assessing vascular invasion (sensitivity 60%–96%) and lymph node metastasis (sensitivity <50%), hindering preoperative planning.
PCCT, an advanced CT technology, uses photon-counting detectors to directly convert X-ray photons into electrical signals, reducing noise and improving image quality. It offers ultra-high spatial resolution (≤0.2 mm in ultra-high-resolution/UHR mode vs ~1 mm for EIDCT) and intrinsic spectral imaging. These features boost tumor-to-parenchyma contrast-to-noise ratio by up to 87% at 40 keV virtual monoenergetic images, sharpening tumor margins.
Clinical evidence shows PCCT outperforms EIDCT in detecting pancreatic cystic lesions (AUC 0.81 vs 0.74) and small structures like submillimeter vessels and 0.8-mm lymph nodes (detection rate 96.6%). It clearly visualizes peripancreatic arterial arcades, celiac ganglia, and neural plexuses, aiding vascular invasion and perineural invasion assessment. Advanced reconstructions like cinematic rendering enable intuitive 3D tumor-vessel visualization for virtual surgical navigation.
Despite benefits, PCCT faces challenges: high system cost, limited availability (mostly tertiary centers), respiratory motion artifacts, and lack of standardized protocols. Most studies are small, single-center trials. Larger multicenter prospective trials are needed to validate its impact on long-term outcomes.
“PCCT’s submillimeter resolution and spectral capabilities address critical limitations of conventional CT for pancreatic cancer,” said corresponding author Prof. Liang Zhu. “It enhances diagnostic precision and surgical planning, with potential to improve patient outcomes as adoption expands.” The review was published online on July 23, 2025, and in Volume 9, Issue 1 of the Journal of Pancreatology on March 01, 2026.
Reference
DOI: http://doi.org/10.1097/JP9.0000000000000233